Clinical trial for Recurrent Solid Tumor
Official title Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
ClinicalTrials.gov ID: NCT04901702
What this study is testing
What is Onivyde?
An investigational intravenous drug being studied for recurrent or refractory solid tumors in children, adolescents, and young adults. It is designed to damage the DNA of cancer cells.
Also referred to as Nanoliposomal irinotecan.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study first finds the highest safe doses of Onivyde with talazoparib or temozolomide. After that, it looks at whether the tumors shrink at those doses.
- Who it's for
- Children, adolescents, or young adults who have a solid tumor that has come back or never fully responded to treatment.
- What's involved
- Participants are randomly assigned to receive either Onivyde plus talazoparib or Onivyde plus temozolomide. They will have regular clinic visits, blood tests, and imaging to monitor safety and tumor response.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 24 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 30
You may be able to join if
- Patients must be \> 12 months and \< 30 years at the time of enrollment on study. Phase I
- Patients with refractory or recurrent non-central nervous system (CNS) solid tumors not amenable to curative treatment are eligible.
- Patients with refractory or recurrent Ewing sarcoma (during or after completion of first-line therapy).
- Patients must have a histologic diagnosis of Ewing sarcoma with EWSR1- FLI1 translocation or other EWS rearrangement at the time of initial...
- Patients must have either measurable or evaluable disease (see Section 7.0 for definitions).
You likely can't join if
- Pregnant or breastfeeding
- Pregnant or breast-feeding women will not be entered on this study. Pregnancy tests must be obtained in girls who are post-menarchal.
- Male and female participants must agree not to donate sperm or eggs, respectively, after the first dose of study drug through 105 days and 45 days...
See the full eligibility criteria
- Patients must be \> 12 months and \< 30 years at the time of enrollment on study. Phase I
- Patients with refractory or recurrent non-central nervous system (CNS) solid tumors not amenable to curative treatment are eligible.
- Patients with refractory or recurrent Ewing sarcoma (during or after completion of first-line therapy).
- Patients must have a histologic diagnosis of Ewing sarcoma with EWSR1- FLI1 translocation or other EWS rearrangement at the time of initial diagnosis.
- Patients must have either measurable or evaluable disease (see Section 7.0 for definitions). Measurable disease includes soft tissue disease evaluable by cross-sectional imaging (RECIST).
- Performance level: Karnofsky \> 50% for patients \> 16 years of age and Lansky \> 50% for patients \< 16 years of age.
- Patients should have received first line therapy and developed either refractory or recurrent disease (first relapse).
- Peripheral absolute neutrophil count (ANC) \>1,000/mm3 (1x109/L)
- Platelet count \> 75,000/mm3 (75x109/L) (no transfusion within 7 days of enrollment)
- Hemoglobin \> 9 g/dL (with or without support) In the phase I study, patients with solid tumors metastatic to bone marrow or with bone marrow hypocellularity defined as \<30% cellularity in at least one bone marrow site...
- Adequate renal function defined as: Creatinine clearance or radioisotope GFR \> 60ml/min/1.73m2 or a serum creatinine maximum based on age/sex: age 6months to \ 16 years, creatinine 1.7 (males) 1.4 (females)
- Adequate liver function defined as: normal liver function as defined by SGPT (ALT) concentration \ 2g/dL.
- Adequate pulmonary function defined as no evidence of dyspnea at rest and a pulse oximetry \> 94% if there is a clinical indication for determination. Pulmonary function tests are not required.
- Myelosuppressive chemotherapy: Patient has not received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (8 weeks if received prior myeloablative therapy).
- Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.
- Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent.
- Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody or 28 days have elapsed since last dose of the monoclonal antibody with complete resolution of...
- Radiotherapy: At least 2 weeks must have elapsed since any irradiation; at least 6 weeks must have elapsed since craniospinal RT, 131I-mIBG therapy or substantial bone marrow irradiation (e.g., \>50% pelvis irradiation).
- Female participant who is post-menarchal must have a negative urine or serum pregnancy test and must be willing to have additional serum and urine pregnancy tests during the study.
- Female or male participant of reproductive potential must agree to use effective contraceptive methods at screening and throughout duration of study treatment.
- Pregnant or breastfeeding
- Pregnant or breast-feeding women will not be entered on this study. Pregnancy tests must be obtained in girls who are post-menarchal.
- Male and female participants must agree not to donate sperm or eggs, respectively, after the first dose of study drug through 105 days and 45 days after the last dose of study drug.
The study team makes the final eligibility decision.
Where it is enrolling
- Palo Alto, California, United States
- Aurora, Colorado, United States
- Washington D.C., District of Columbia, United States
- Atlanta, Georgia, United States
- Minneapolis, Minnesota, United States
- Memphis, Tennessee, United States
- Toronto, Ontario, Canada
- Montreal, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 24 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 12 months to 30 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Palo Alto, California, United States; Aurora, Colorado, United States; Washington D.C., District of Columbia, United States; Atlanta, Georgia, United States; Minneapolis, Minnesota, United States; Memphis, Tennessee, United States and 2 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.